[go: up one dir, main page]

WO2003027321A3 - Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin - Google Patents

Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin Download PDF

Info

Publication number
WO2003027321A3
WO2003027321A3 PCT/IB2002/004158 IB0204158W WO03027321A3 WO 2003027321 A3 WO2003027321 A3 WO 2003027321A3 IB 0204158 W IB0204158 W IB 0204158W WO 03027321 A3 WO03027321 A3 WO 03027321A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurogranin
diagnosis
treatment
methods
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/004158
Other languages
French (fr)
Other versions
WO2003027321A2 (en
Inventor
Finn Skou Pedersen
Annette Balle Soerensen
Anne Ahlmann Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Priority to AU2002330713A priority Critical patent/AU2002330713A1/en
Publication of WO2003027321A2 publication Critical patent/WO2003027321A2/en
Publication of WO2003027321A3 publication Critical patent/WO2003027321A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel compositions and methods related to Neurogranin for use in diagnosis and treatment of lymphoma and leukemia. In addition, the present invention describes the use of such novel compositions for use in screening methods.
PCT/IB2002/004158 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin Ceased WO2003027321A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002330713A AU2002330713A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/962,916 2001-09-24
US09/962,854 2001-09-24
US09/962,855 2001-09-24
US09/962,929 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/963,131 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Publications (2)

Publication Number Publication Date
WO2003027321A2 WO2003027321A2 (en) 2003-04-03
WO2003027321A3 true WO2003027321A3 (en) 2003-11-06

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 Ceased WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
PCT/IB2002/004197 Ceased WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 Ceased WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
PCT/IB2002/004123 Ceased WO2003027320A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
PCT/IB2002/004134 Ceased WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/IB2002/004197 Ceased WO2003027295A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of jak1
PCT/IB2002/005830 Ceased WO2003043565A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
PCT/IB2002/004123 Ceased WO2003027320A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
PCT/IB2002/004134 Ceased WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Country Status (2)

Country Link
AU (4) AU2002364889A1 (en)
WO (5) WO2003027321A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959969A2 (en) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
CA2642266A1 (en) * 2006-02-14 2007-08-23 President And Fellows Of Harvard College Mitotic progression genes and methods of modulating mitosis
WO2020247914A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
WO2000037483A1 (en) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative disorders
WO2001030973A2 (en) * 1999-10-25 2001-05-03 Princeton University Genetic sequences associated with neural cell proliferation and disease
WO2001034633A2 (en) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening for active agents
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
WO1998020126A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
CA2290738A1 (en) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Nucleic acid arrays
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
CA2321132A1 (en) * 1998-02-23 1999-08-26 Andrei V. Gudkov P53-dependent secretion of growth inhibitory factors
ES2222705T3 (en) * 1998-04-17 2005-02-01 Parker Hughes Institute BTK INHIBITORS AND METHODS FOR IDENTIFICATION AND USE.
DE19817947A1 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
IL151079A0 (en) * 2000-02-07 2003-04-10 Quark Biotech Inc Fas pathway genes
HRP20020838A2 (en) * 2000-04-25 2004-12-31 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
KR100830859B1 (en) * 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 Imidazopyridine derivatives and pharmaceutical compositions containing the same
US20020040127A1 (en) * 2000-06-09 2002-04-04 Yuqiu Jiang Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
AU2001290699A1 (en) * 2000-09-08 2002-03-22 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
EP1362122A2 (en) * 2000-09-12 2003-11-19 TransGenetics Incorporated Microarrayed organization of transcription factor target genes
WO2002022882A2 (en) * 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Methods of inhibiting kinases
DE60232059D1 (en) * 2001-03-01 2009-06-04 Epigenomics Ag METHOD FOR DEVELOPING SKILLS FOR DIAGNOSTIC AND THERAPEUTIC USES BASED ON THE EXPRESSION AND METHYLATION STATUS OF THE GENES
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
WO2000037483A1 (en) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative disorders
WO2001030973A2 (en) * 1999-10-25 2001-05-03 Princeton University Genetic sequences associated with neural cell proliferation and disease
WO2001034633A2 (en) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening for active agents
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 9 March 2001 (2001-03-09), XP002250336, retrieved from EBI accession no. EM_HUM:BC002835 Database accession no. BC002835 *
MARTINEZ DE ARRIETA CRUZ ET AL: "Structure, organization, and chromosomal mapping of the human neurogranin gene (NRGN).", GENOMICS, vol. 41, no. 2, 1997, pages 243 - 249, XP002250334, ISSN: 0888-7543 *
PAK JHANG HO ET AL: "Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: A study with knockout mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 21, 10 October 2000 (2000-10-10), October 10, 2000, pages 11232 - 11237, XP002250333, ISSN: 0027-8424 *
SVAREN JOHN ET AL: "EGR1 target genes in prostate carcinoma cells identified by microarray analysis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 49, 8 December 2000 (2000-12-08), pages 38524 - 38531, XP002250335, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2003027276A3 (en) 2004-02-12
WO2003043565A3 (en) 2003-11-13
WO2003027295A3 (en) 2003-10-16
AU2002337442A1 (en) 2003-04-07
WO2003027276A2 (en) 2003-04-03
AU2002330713A1 (en) 2003-04-07
AU2002364889A1 (en) 2003-06-10
WO2003027295A2 (en) 2003-04-03
WO2003027320A3 (en) 2003-10-23
WO2003027320A2 (en) 2003-04-03
AU2002364889A8 (en) 2003-06-10
AU2002329000A1 (en) 2003-04-07
WO2003027321A2 (en) 2003-04-03
WO2003043565A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2003008583A3 (en) Novel compositions and methods for cancer
EP2014669A3 (en) Compositions and methods for cancer
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
WO2003045230A3 (en) Novel compositions and methods for cancer
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
EP3738591A3 (en) Novel antibacterial agents
SG2010079697A (en) Aminocyclohexyl ether compounds and uses thereof
GB0111186D0 (en) Novel compounds
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2003045324A3 (en) 14-methyl-epothilones
CA2436572A1 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2003035837A3 (en) Novel compositions and methods for cancer
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis
WO2003039484A3 (en) Novel compositions and methods for cancer
WO2003027321A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP